Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company that reports frequent updates related to its efforts to develop therapies for RAS/MAPK pathway-driven cancers. News about Erasca often centers on progress within its RAS-targeting franchise, including clinical, preclinical, regulatory, and intellectual property developments.
Investors following ERAS news can expect detailed announcements on the advancement of the company’s key product candidates, ERAS-0015 and ERAS-4001. Erasca issues releases on milestones such as investigational new drug (IND) clearances, initiation and progress of Phase 1 trials, and early clinical observations in patients with RAS-mutant and KRAS-mutant solid tumors. The company also reports on patent issuances that extend composition of matter protection for its molecules and on scientific presentations at major oncology and healthcare conferences.
Erasca’s news flow includes quarterly business updates and financial results, typically accompanied by commentary from management on the status of the AURORAS-1 and BOREALIS-1 trials, cash resources, and research and development priorities. The company additionally announces participation in investor conferences hosted by firms such as J.P. Morgan, Evercore, Guggenheim, Stifel, Jefferies, Goldman Sachs, and Morgan Stanley, where its leadership discusses strategy and pipeline progress.
For readers tracking ERAS, this news stream provides insight into how Erasca is advancing its clinical-stage programs targeting RAS and KRAS, how it is building its intellectual property position, and how management frames the opportunities and risks associated with its focus on RAS/MAPK pathway-driven cancers.
On February 1, 2023, Erasca, Inc. (Nasdaq: ERAS) announced its participation in the Guggenheim Oncology Conference 2023. The event will feature a fireside chat with CEO Jonathan E. Lim, M.D., and CFO David M. Chacko at 1:00 PM ET on February 8, 2023. They will also engage in one-on-one investor meetings. A live webcast will be available, with an archived replay accessible for 30 days post-event. Erasca focuses on developing therapies for patients with RAS/MAPK pathway-driven cancers, aiming to be a leader in precision oncology.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 am PT. CEO Dr. Jonathan E. Lim will present an overview of the company and its RAS/MAPK pathway-focused pipeline in Elizabethan Room C of the Westin St. Francis Hotel, San Francisco. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days.
Erasca, Inc. (Nasdaq: ERAS) announced the dosing of the first patient in the HERKULES-1 Phase 1b trial, evaluating the ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors. The trial aims to assess safety and efficacy in RAS/MAPK pathway-altered tumors. Preliminary data showed positive responses; 44% of patients with BRAF-driven tumors exhibited responses to either monotherapy ERAS-007 or ERAS-601. This highlights the potential of targeting BRAF Class 2 and 3 alterations, which currently lack approved therapies, representing a significant unmet need in oncology.
Erasca, Inc. (Nasdaq: ERAS) announced FDA clearance of an IND application for ERAS-3490, a small molecule KRAS G12C inhibitor aimed at treating solid tumors with high CNS penetration. The drug targets the KRAS G12C mutation, prevalent in various cancers, including non-small cell lung cancer (NSCLC), where CNS metastases affect up to 40% of patients. Nonclinical data show strong anti-tumor activity and survival benefits in relevant cancer models, underscoring the potential of ERAS-3490 in precision oncology.
Erasca, Inc. (Nasdaq: ERAS) has entered a $100 million equity offering to support its exclusive worldwide license agreement with Novartis for naporafenib, a promising cancer treatment targeting NRAS mutant melanoma and other RAS/MAPK-driven tumors. Naporafenib has been evaluated in over 500 patients, showing strong safety and efficacy as both a single agent and in combination therapies. The agreement includes a $20 million upfront cash payment and stock issuance, and could yield up to $280 million in milestone payments for Novartis. A conference call will elaborate on these developments.
Erasca, Inc. (Nasdaq: ERAS) announced a pricing of an underwritten offering of 15,384,616 shares of common stock at $6.50 each, aiming to raise approximately $100 million. All shares are offered by Erasca, expected to close on December 13, 2022, pending customary closing conditions. Proceeds will support research and development of product candidates, working capital, and general corporate purposes. The offering is filed under a previously effective shelf registration with the SEC.
ERAS-007, a promising ERK1/2 inhibitor, is undergoing evaluation in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer (mCRC). Erasca has formed a clinical trial collaboration with Pierre Fabre to facilitate this study, broadening its reach in Europe and Asia Pacific. Encorafenib, previously approved for mCRC, shows limited efficacy, with only 20% of patients responding. The aim of this combination therapy is to enhance treatment outcomes by reducing resistance mechanisms. This partnership complements existing collaborations with Pfizer.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced presentations at two upcoming investor conferences. The 5th Annual Evercore ISI HealthCONx Conference will be held virtually from November 29 to December 1, with a fireside chat scheduled for November 29 at 8:50 AM EST. Additionally, the Bank of America SMID Cap Conference is set for December 7-8, featuring a fireside chat on December 8 at 11:25 AM EST. Archived replays of both events will be available until February 2023. Visit Erasca.com/events for more details.
Erasca, Inc. (Nasdaq: ERAS) reported promising preliminary data for its lead candidates, ERAS-007 and ERAS-601, demonstrating efficacy in advanced solid tumors. The company signed clinical trial collaboration agreements with Eli Lilly and Pfizer to explore combination treatments with cetuximab and palbociclib, respectively. Erasca's robust balance sheet shows $365 million in cash, ensuring operational funding into mid-2024. However, R&D expenses rose to $28.2 million and net loss was $35.5 million for Q3 2022, though improving from Q3 2021.
Erasca, Inc. (Nasdaq: ERAS) announced a clinical trial collaboration and supply agreement with Pfizer to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with the CDK4/6 inhibitor palbociclib for patients with KRAS- and NRAS-mutant colorectal and pancreatic cancers. This study is part of the Phase 1b/2 HERKULES-3 trial, sponsored by Erasca. Approximately 1.8 million cases of colorectal cancer and 0.5 million cases of pancreatic cancer are diagnosed annually, with a significant portion harboring RAS mutations. The combination aims to enhance treatment efficacy and reduce resistance.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
